Views: 128 2026-10-06 GSK is a British pharmaceutical and vaccine maker with £32.7bn of 2025 sales. It earns money in three areas: Specialty Medicines (£13.5bn, led by HIV through its majority-owned ViiV Healthcare, plus respiratory, immunology and oncology), Vaccines (£9.2bn, led by the shingles vaccine Shingrix and the RSV vaccine Arexvy) and General Medicines (£10.0bn, mostly mature inhalers such as Trelegy). It spun off its consumer arm, Haleon, in 2022. The investment debate centres on one question: can new drugs replace sales of dolutegravir, its HIV backbone, when patents lapse between 2028 and 2030? Management promises more than £40bn of …
GSK at $46: A Cheap Pharma Giant Racing Its Own Patent ClockRead More »
This content is restricted to site members. If you are an existing user, please log in. New users may register below.